Personalized approach for direct oral anticoagulant prescription: from theory to practice

Personalized approach for direct oral anticoagulant prescription: from theory to practice

Data on possibilities of personalized approach for direct oral anticoagulants (DOAC) choice in patients with atrial fibrillation are presented in the article. We also review clinical and fundamental studies and future perspectives on pharmacogenetic and pharmacokinetic tests to predict the efficacy...

Full description

Bibliographic Details
Main Authors:	A I Skripka, V V Kogay, A I Listratov, A A Sokolova, D A Napalkov, V V Fomin
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2019-07-01
Series:	Терапевтический архив
Subjects:	direct oral anticoagulants apixaban dabigatran rivaroxaban edoxaban pharmacogenetics pharmacokinetics personalized approach
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/33649

Similar Items

PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION
by: A. V. Kryukov, et al.
Published: (2017-07-01)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01)

Direct oral anticoagulants; a review for the non-specialist
by: Thilina Gunawardena
Published: (2021-11-01)

Are outpatient anticoagulation management services the wave of the future (again)?
by: Bethany Samuelson Bannow
Published: (2022-05-01)

Anticoagulation in the early phase of non-valvular atrial fibrillation-related acute ischemic stroke: where do we stand?
by: Luca Masotti, et al.
Published: (2019-01-01)

Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics
by: Luca Masotti, et al.
Published: (2013-12-01)

DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS
by: S. N. Bel'diev, et al.
Published: (2017-11-01)

DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT
by: D. А. Napalkov, et al.
Published: (2017-03-01)

Direct oral anticoagulants: a guide for daily practice
by: Pierre Fontana, et al.
Published: (2016-02-01)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
by: Heike Schwarb, et al.
Published: (2016-03-01)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
by: Paolo Zappulla, et al.
Published: (2021-04-01)

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
by: Nicola Ferri, et al.
Published: (2022-05-01)

Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants
by: Ju Yup Lee
Published: (2018-12-01)

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management
by: Martina Mookadam, et al.
Published: (2015-01-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
by: Sergey Nikolaevich Bel'diev, et al.
Published: (2017-11-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
by: Sergey Nikolaevich Bel'diev, et al.
Published: (2017-11-01)

Direct oral anticoagulants in atrial fibrillation patients aged 75 years or older: Efficacy and safety balance
by: V V Fomin, et al.
Published: (2017-04-01)

Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers
by: Ramin Artang, et al.
Published: (2019-07-01)

Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
by: Konstantinos N. Aronis, et al.
Published: (2018-02-01)

IMPACT OF NON-VITAMIN K ORAL ANTI-COAGULANTS ON WARFARIN UTILISATION AND NHS BUDGET IN UK
by: Mohammed Aladul, et al.
Published: (2022-09-01)

New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants
by: K. B. Mirzaev, et al.
Published: (2020-11-01)

Pharmacogenetics of new oral anticoagulants
by: Bella A. Azimova, et al.
Published: (2023-04-01)

The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants
by: Grzegorz Grześk, et al.
Published: (2021-08-01)

Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence
by: Willett KC, et al.
Published: (2017-04-01)

SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A TWO-YEAR COHORT STUDY
by: A. V. Zhilenko, et al.
Published: (2017-07-01)

The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
by: Brendan Wood, et al.
Published: (2017-08-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials
by: Yi-Dan Yan, et al.
Published: (2018-06-01)

Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art
by: S. R. Gilyarevsky
Published: (2022-07-01)

PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS
by: A. А. Sokolova, et al.
Published: (2017-12-01)

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
by: Turagam MK, et al.
Published: (2015-09-01)

Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
by: M. A. Gabitova, et al.
Published: (2020-01-01)

A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
by: Michele Malagù, et al.
Published: (2023-03-01)

Incidence of Osteoporosis in Primary Care Patients with Atrial Fibrillation Receiving Different Oral Anticoagulants
by: Woldesellassie M. Bezabhe, et al.
Published: (2022-10-01)

Direct oral anticoagulants compared to warfarin in long‐term management of cerebral venous thrombosis: A comprehensive meta‐analysis
by: Redoy Ranjan, et al.
Published: (2024-02-01)

Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants
by: S. R. Gilyarevsky, et al.
Published: (2023-07-01)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
by: V. I. Petrov, et al.
Published: (2016-12-01)

Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants
by: A. D. Aga, et al.
Published: (2023-01-01)

Anticoagulant therapy in patients with atrial fibrillation and reduced kidney function of diabetic and non-diabetic etiologies
by: A A Sokolova, et al.
Published: (2017-12-01)